Lastest Publication demostrating Solexan™ with Potent Antimicrobial Activity for Treating Impetigo

Uncomplicated topical skin infections like impetigo, caused by gram-positive bacteria such as Staphylococcus aureus and Streptococcus pyogenes, are a common global health issue, particularly affecting school-aged children.

With increasing antimicrobial resistance, conventional treatments such as mupirocin are becoming ineffective, highlighting the necessity for new antimicrobial development. Fatty acids have long shown potential as novel antimicrobials, but their development has been limited by solubility and efficacy concerns in topical applications.

We discovered that Solexan™ (GS-1), a combination of L-arginine, an amino acid, with undecylenic acid, an 11-carbon fatty acid, produced a water-soluble ammonium carboxylate salt, arginine undecylenate, produced a potent antibacterial effect against the gram-positive coccobacilli responsible for common skin and soft tissue infections such as impetigo.

No evidence of resistance against Solexan™ was observed across multiple exposure whilst demonstrating a well-tolerated efficacy at clearing MRSA infection in vivo with no signs of toxicity associated with the treatment. Solexan™ presents with significant potential as a topical treatment for uncomplicated skin infections involving MRSA, MSSA, and S. pyogenes. This research marks a key step forward exploring Solexan™’s applications in fighting bacterial infections, offering an alternative to existing treatments.This research marks a key step forward exploring Solexan™’s applications in fighting bacterial infections, offering an alternative to existing treatments.

To find out more about our publication, click here.

To find out more about impetigo from NHMRC, click here.

And to find out more about our ZosterEase clinical trial into shingles, click here.

‍